Emergent BioSolutions Receives Orphan Drug Designation for BioThrax for Post-Exposure Prophylaxis of Anthrax Disease
Emergent BioSolutions Inc. (NYSE:EBS) announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to BioThrax® (Anthrax Vaccine Adsorbed) for post-exposure...
Emergent BioSolutions to Participate in May 2014 Investor Conferences
Apr. 17, 2014-- Emergent BioSolutions Inc. (NYSE: EBS) announced today that a member of the company’s senior management team will participate in the following investor conferences in May...
Emergent BioSolutions Successfully Completes Pivotal Clinical Study to Support Expanded Indication for BioThrax
Emergent BioSolutions Inc. (NYSE:EBS) today announced successful completion of the last licensure-enabling study in its BioThrax® (Anthrax Vaccine Adsorbed) Post-Exposure Prophylaxis (PEP) program....
Emergent BioSolutions Reports Financial Results for 2013
Emergent BioSolutions Inc. (NYSE: EBS) announced today its financial results for the fourth quarter and full year ended December 31, 2013. For the full year 2013, total revenues were $312.7 million...
Emergent BioSolutions to Release Fourth Quarter and Full Year 2013 Financial Results and Conduct a Conference Call on March 6, 2014
mergent BioSolutions Inc. (NYSE: EBS) announced today that it will report financial results for the fourth quarter and full year 2013 on Thursday, March 6, 2014, after market close. Company...
Emergent BioSolutions Completes Acquisition of Cangene Corporation
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has completed its acquisition of Cangene Corporation for $222 million in cash. After payment by Cangene of transaction related costs,...
Emergent BioSolutions Announces Completion of $250 Million Convertible Senior Notes Offering
Emergent BioSolutions Inc. (NYSE: EBS) announced today the closing of its previously announced offering of 2.875% Convertible Senior Notes due 2021 in a private placement to qualified institutional...
Emergent BioSolutions Announces Expiration of the Hart-Scott-Rodino Waiting Period for Emergent’s Acquisition of Cangene Corporation
Emergent BioSolutions Inc. (NYSE: EBS) announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, in connection with Emergent’s proposed acquisition of...
Emergent BioSolutions Announces $35 Million Option Exercised by the Initial Purchasers of the Company’s Convertible Senior Notes
Emergent BioSolutions Inc. (“Emergent”) (NYSE:EBS) announced today that the initial purchasers have exercised in full their option to purchase an additional $35 million principal amount of its...
Emergent BioSolutions Announces Pricing of Offering of $215 Million of 2.875% Convertible Senior Notes
Emergent BioSolutions Inc. (“Emergent”) (NYSE: EBS) announced today the pricing of its offering of $215 million aggregate principal amount of 2.875% Convertible Senior Notes due 2021 (the...
Emergent BioSolutions Announces Proposed Offering of $200 Million Convertible Senior Notes
Emergent BioSolutions Inc. (“Emergent”) (NYSE: EBS) announced today that it intends to offer, subject to market and other conditions, $200 million aggregate principal amount of Convertible Senior...
Emergent BioSolutions Announces Preliminary 2013 Financial Results and Provides 2014 Forecast
Emergent BioSolutions Inc. (NYSE:EBS) today announced preliminary 2013 financial results and provided guidance for...